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BACKGROUND
The use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result 
in better postoperative outcomes than the use of saphenous-vein grafts. However, 
randomized, controlled trials comparing radial-artery grafts and saphenous-vein 
grafts have been individually underpowered to detect differences in clinical out-
comes. We performed a patient-level combined analysis of randomized, controlled 
trials to compare radial-artery grafts and saphenous-vein grafts for CABG.
METHODS
Six trials were identified. The primary outcome was a composite of death, myo-
cardial infarction, or repeat revascularization. The secondary outcome was graft 
patency on follow-up angiography. Mixed-effects Cox regression models were 
used to estimate the treatment effect on the outcomes.
RESULTS
A total of 1036 patients were included in the analysis (534 patients with radial-
artery grafts and 502 patients with saphenous-vein grafts). After a mean (±SD) 
follow-up time of 60±30 months, the incidence of adverse cardiac events was 
significantly lower in association with radial-artery grafts than with saphenous-
vein grafts (hazard ratio, 0.67; 95% confidence interval [CI], 0.49 to 0.90; 
P = 0.01). At follow-up angiography (mean follow-up, 50±30 months), the use of 
radial-artery grafts was also associated with a significantly lower risk of occlu-
sion (hazard ratio, 0.44; 95% CI, 0.28 to 0.70; P<0.001). As compared with the 
use of saphenous-vein grafts, the use of radial-artery grafts was associated with 
a nominally lower incidence of myocardial infarction (hazard ratio, 0.72; 95% 
CI, 0.53 to 0.99; P = 0.04) and a lower incidence of repeat revascularization (haz-
ard ratio, 0.50; 95% CI, 0.40 to 0.63; P<0.001) but not a lower incidence of death 
from any cause (hazard ratio, 0.90; 95% CI, 0.59 to 1.41; P = 0.68).
CONCLUSIONS
As compared with the use of saphenous-vein grafts, the use of radial-artery grafts 
for CABG resulted in a lower rate of adverse cardiac events and a higher rate of 
patency at 5 years of follow-up. (Funded by Weill Cornell Medicine and others.)
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Despite the recommendations of the current guidelines, the use of multi-ple arterial grafts for coronary-artery 
bypass grafting (CABG) has not been widely 
adopted by the surgical community, and the 
great majority of patients in North America and 
Europe currently receive saphenous-vein grafts 
in addition to an internal-thoracic-artery graft to 
the left anterior descending coronary artery.1 
Resistance among surgeons to the use of multi-
ple arterial grafts can be explained, at least in 
part, by the fact that the clinical benefit of addi-
tional arterial grafts that has been reported in 
observational studies has not been confirmed 
in randomized clinical trials.2 Although several 
trials have shown higher rates of angiographic 
patency in association with radial-artery grafts 
than with saphenous-vein grafts,2 these trials 
were individually underpowered to detect differ-
ences in the frequency of clinical events. There-
fore, whether the use of radial-artery grafts can 
improve clinical outcomes remains unknown. To 
overcome the limitations of individual trials in 
detecting differences in clinical outcomes, we per-
formed a patient-level combined analysis of ran-
domized trials in which radial-artery grafts were 
compared with saphenous-vein grafts for CABG.
Me thods
RADIAL Project
The Radial Artery Database International Alliance 
(RADIAL) project was initiated in March 2015 
by a group of clinical investigators conducting 
trials and research related to radial-artery graft-
ing. One key aim of the project was to combine 
individual patient–level data from individual 
trials in which the use of the radial artery is 
compared with the use of other conduits for 
CABG to provide the basis for a combined analy-
sis. The full list of the RADIAL investigators and 
the list of the detailed individual contributions 
to this study are provided in the Supplementary 
Appendix, available with the full text of this arti-
cle at NEJM.org. The authors vouch for the accu-
racy and completeness of the data presented.
Search Strategy and Trial Selection
The present analysis includes only randomized 
trials in which long-term (≥2 years) outcomes 
were assessed among patients who were ran-
domly assigned to undergo either radial-artery 
grafting or saphenous-vein grafting to supple-
ment left internal-thoracic-artery grafting during 
isolated CABG surgery. The full search strategy 
is described in the Supplementary Appendix.
After the identification of trials for inclusion, 
we compared trial protocols and publications 
from each trial and then provided a detailed 
specification of core minimum data require-
ments to each trial team to prepare the data for 
pooling. After receipt of the data, they were 
checked for missing values and for consistency. 
Data queries were resolved through direct con-
sultation with each trial team before analysis. 
The most up-to-date follow-up information was 
also requested from the trial investigators. Renal 
insufficiency was defined as a preoperative serum 
creatinine level of more than 1.5 mg per deciliter 
(130 μmol per liter).3
The design of the analysis was published a 
priori on the International Prospective Register 
of Systematic Reviews (registration number, 
CRD42017077562). The present article was writ-
ten in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
(PRISMA) recommendations.
Outcomes
The primary outcome was a composite of major 
adverse cardiac events during follow-up and in-
cluded death, myocardial infarction, and repeat 
revascularization. Each component of the com-
posite outcome was also analyzed individually. 
Prespecified subgroup analyses of the primary 
outcome were performed according to age, sex, 
diabetes status, history of myocardial infarction, 
left ventricular ejection fraction (<35% or ≥35%), 
presence or absence of preoperative renal insuf-
ficiency, and radial-artery graft target vessel. 
The secondary outcome was graft patency at the 
protocol-defined follow-up angiographic exami-
nation. The patency rate was graded according 
to the FitzGibbon classification,4 which grades 
graft patency as A (widely patent), B (flow limit-
ed), or O (occluded). For the purposes of our 
analysis, grades A and B were considered patent 
and grade O occluded.
Statistical Analysis
Baseline categorical variables were reported as 
counts and percentages and were compared with 
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the use of a conditional regression analysis 
stratified according to trial. Baseline continuous 
variables were reported as means and standard 
deviations and were compared with a two-way 
analysis of variance stratified according to trial. 
Outcomes were reported as raw numbers and 
linearized event rates per 1000 patient-years to 
account for different follow-up durations among 
the trials. Cumulative incidences were determined 
and are presented graphically.
The primary analysis of clinical and angio-
graphic end points was performed on the basis 
of the intention-to-treat principle with the use of 
a one-stage approach. Data were combined in a 
single data set and fitted in a Cox regression 
model stratified according to trial, with trial 
identifiers used as random effects. A competing-
risk framework was used to compute pseudo–
hazard ratios for myocardial infarction and 
repeat revascularization.5 Treatment effects are 
presented as hazard ratios and 95% confidence 
intervals. The proportional-hazards assumptions 
were verified with the use of Schoenfeld residuals. 
Multivariable Cox models were implemented to 
investigate independent risk factors for graft oc-
clusion, including baseline characteristics and 
the long-term use of agents for the prevention of 
arterial-graft spasm.
For the primary outcome, subgroup and inter-
action-term analyses were used to investigate the 
prespecified possible effect modifiers. A non-
linear relationship between age and treatment 
effect was investigated by comparing model fit-
ting with age used as a linear term versus with 
age used as a spline function with an increasing 
number of knots. A potential age cutoff for the 
loss of benefit with the radial artery was evalu-
ated with nonparametric computation of boot-
strap pointwise confidence limits across a range 
of ages.
As a sensitivity analysis, the treatment effect 
on the primary outcome was reestimated in an 
as-treated analysis with a two-step approach. 
The as-treated analysis was implemented with 
the conduit received used as the treatment indi-
cator, thus accounting for crossovers between 
treatment groups. For the two-stage approach, 
data on individual participants were first ana-
lyzed in each trial independently with Cox re-
gression. This step produced aggregate data for 
each trial with a mean treatment effect estimate 
and its standard error. Aggregate data were then 
synthesized in the second step, in which the 
generic inverse variance method was used with 
a fixed effect when I2 was less than 50% and a 
random effect when I2 was greater than or equal 
to 50%. An influence analysis was used to assess 
the influence of individual trials on the final 
estimate. Publication bias was evaluated with 
the use of a funnel plot and linear regression 
test for asymmetry. In a sensitivity analysis of 
graft occlusion that included angiographic data 
from the Radial Artery Patency Study (RAPS), a 
mixed model based on graft type was used with 
individual trials as a random effect (see the 
Supplementary Appendix).
In a supplementary analysis, a generalized 
mixed-effects logistic regression with the origi-
nal trials used as a random effect was performed 
to assess the effect of conduit selection on the 
risk of perioperative stroke. The saphenous-vein 
group was used as the reference in all analyses. 
All P values are two-sided. P values of less than 
0.05 were considered to indicate statistical signifi-
cance, without correction for multiple testing. 
Statistical analyses were performed with R soft-
ware, version 3.2.3 (R Foundation).
R esult s
Trial Selection
From 612 titles of articles, 38 pertinent trials 
were identified and included in a full-text review. 
After review, 32 trials were excluded because 
they did not meet the inclusion criteria. A total 
of 6 randomized trials were selected for the pres-
ent analysis,6-11 including a total of 1305 patients 
with 5266 patient-years of follow-up. Further 
details and the PRISMA flowchart and checklist 
are provided in Figure S1 and Table S1 in the 
Supplementary Appendix. An overview of the 
included trials is provided in Table 1. The prin-
cipal investigators of the 6 individual trials were 
contacted, and all agreed to provide data on in-
dividual patients. The principal investigators of 
the Stand-in-Y trial also provided updated follow-
up data.
Some of the individual trials had important 
design issues that were addressed before pooling 
of the data. In the Stand-in-Y trial, saphenous-
vein grafts were compared with either radial-
artery grafts or right internal-thoracic-artery 
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grafts in different treatment groups.7 The Radial 
Artery Patency and Clinical Outcomes (RAPCO) 
trial consisted of two separate trials, one of radial-
artery grafts versus right internal-thoracic-artery 
grafts and one of radial-artery grafts versus sa-
phenous-vein grafts.9 For the present analysis, 
only patients who were included in the compari-
son between radial-artery grafts and saphenous-
vein grafts were included from the Stand-in-Y 
and RAPCO trials. The trial by Petrovic et al. had 
no per-protocol angiographic examination, and 
patients underwent repeat angiographic exami-
nations only for clinical indications.10 The angio-
graphic results of this trial were therefore not 
used for our analyses of graft occlusion. In 
RAPS, each patient received both a radial-artery 
graft and a saphenous-vein graft, and random-
ization was performed for the target coronary 
territory (i.e., “within-patient” randomization).11 
Because of the difficulty of attributing clinical 
events to the radial-artery graft or the saphe-
nous-vein graft for any given patient, this trial 
was used only for the sensitivity analysis of graft 
occlusion (see the Supplementary Appendix).
Combined Analysis
Overall, 534 patients who received radial-artery 
grafts and 502 patients who received saphenous-
vein grafts were included in the comparison of 
clinical outcomes. The baseline characteristics 
of these patients are summarized in Table 2. 
Age, sex, diabetes prevalence, severe left ventricu-
lar dysfunction (left ventricular ejection fraction 
<35%), and the prevalence of renal insufficiency 
were similar in the two groups. Endoscopic har-
vesting of either the saphenous vein or the radial 
artery was not used in any trial. The total num-
ber of grafts performed was similar in the radi-
al-artery group and the saphenous-vein group. 
The target vessel was the left circumflex coro-
nary artery and the right coronary artery in ap-
proximately 75% and 25% of cases, respectively.
The main outcomes of the combined analysis 
are reported in Table 3. The mean (±SD) follow-
up time was 60±30 months (median, 60; inter-
quartile range, 39 to 83; range, 0 to 146). The 
incidence of the composite primary outcome of 
death, myocardial infarction, or repeat revascu-
larization was significantly lower in the radial-
artery group than in the saphenous-vein group 
(25 vs. 39 events per 1000 patient-years; hazard 
ratio, 0.67; 95% confidence interval [CI], 0.49 to T
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0.90; P = 0.01) (Fig. 1A). Radial-artery grafts were 
associated with a nominally lower incidence of 
myocardial infarction (6 vs. 9 per 1000 patient-
years; hazard ratio, 0.72; 95% CI, 0.53 to 0.99; 
P = 0.04) and a lower incidence of repeat revascu-
larization (9 vs. 17 per 1000 patient-years; haz-
ard ratio, 0.50; 95% CI, 0.40 to 0.63; P<0.001) 
but not of death from any cause (15 and 17 per 
1000 patient-years; hazard ratio, 0.90; 95% CI, 
0.59 to 1.41; P = 0.68) (Fig. S2 in the Supplemen-
tary Appendix).
A total of 345 of 434 patients (79%) in the 
radial-artery group and 307 of 402 patients 
(76%) in the saphenous-vein group underwent 
Characteristic
Radial-Artery Group 
(N = 534)
Saphenous-Vein Group 
(N = 502) P Value
Age — yr 66.6±9.28 67.1±9.83 0.42
Female sex — no. (%) 158 (29.6) 151 (30.1) 0.92
Diabetes — no. (%) 181 (33.9) 177 (35.3) 0.69
Previous myocardial infarction — no. (%) 164 (30.7) 160 (31.9) 0.74
Elective admission — no. (%) 469 (87.8) 456 (90.8) 0.14
Renal insufficiency — no. (%)† 45 (8.4) 46 (9.2) 0.76
Left ventricular ejection fraction <35% — no. (%) 25 (4.7) 32 (6.4) 0.29
Target vessel — no. (%) 0.13
Left circumflex coronary artery 415 (77.7) 369 (73.5)
Right coronary artery 119 (22.3) 133 (26.5)
No. of grafts 3.1±0.65 3.1±0.55 0.53
Proximal anastomosis site — no. (%) 0.10
Ascending aorta 489 (91.6) 474 (94.4)
Internal thoracic artery 45 (8.4) 28 (5.6)
*  Plus–minus values are means ±SD.
†  Renal insufficiency was defined as a preoperative serum creatinine level of more than 1.5 mg per deciliter.3
Table 2. Characteristics of the Patients at Baseline.*
Outcome
Radial-Artery Group 
(N = 534)
Saphenous-Vein Group 
(N = 502) Treatment Effect†
No. of Events 
(%)
Events per 1000 
Patient-Yr‡
No. of Events 
(%)
Events per 1000 
Patient-Yr‡
Hazard Ratio 
(95% CI) P Value
Death, myocardial infarction,  
or repeat revascularization
67 (12.5) 25 94 (18.7) 39 0.67 (0.49–0.90) 0.01
Death 40 (7.5) 15 42 (8.4) 17 0.90 (0.59–1.41) 0.68
Myocardial infarction 16 (3.0) 6 21 (4.2) 9 0.72 (0.53–0.99) 0.04
Repeat revascularization 23 (4.3) 9 43 (8.6) 17 0.50 (0.40–0.63) <0.001
Graft occlusion§ 28/345 (8.1) 19 61/307 (19.9) 46 0.44 (0.28–0.70) <0.001
*  The analyses of clinical outcomes included all patients enrolled in the RAPCO, RSVP, Stand-in-Y, Yoo and colleagues, and Petrovic et al. trials.
†  Results are from a mixed-effect Cox regression model with individual trials included as a random effect (saphenous-vein group is the refer-
ence group).
‡  The total numbers of patient-years were 2675 in the radial-artery group and 2510 in the saphenous-vein group.
§  The main analysis of graft occlusion included all the patients with follow-up angiography with data available from the RAPCO, RSVP, Stand-
in-Y, and Yoo and colleagues trials. Data were available for 345 of 434 radial-artery grafts (1454 patient-years) and 307 of 402 saphenous-
vein grafts (1311 patient-years).
Table 3. Main Outcomes.*
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protocol-defined follow-up angiography. A com-
parison of the baseline characteristics between 
patients with follow-up angiographic data avail-
able and those without such data available is 
shown in Table S2 in the Supplementary Appen-
dix. The mean follow-up time to protocol angi-
ography was 50±30 months (median, 51; inter-
quartile range, 29 to 68; range, 1 to 143). The 
incidence rates for graft occlusion were 19 events 
per 1000 patient-years in the radial-artery group 
versus 46 events per 1000 patient-years in the 
saphenous-vein group; radial-artery grafts were 
associated with a significantly lower risk of oc-
clusion (hazard ratio, 0.44; 95% CI, 0.28 to 0.70; 
P<0.001) (Fig. 1B).
The results of the sensitivity analyses were 
consistent with the main analysis (Figs. S3, S4, 
and S5 and Table S3 in the Supplementary Ap-
pendix). A funnel plot of the included trials did 
not suggest evidence of publication bias (P = 0.32) 
(Fig. S6 in the Supplementary Appendix). No 
significant difference in the rate of perioperative 
stroke was found between the two groups (0.7% 
in the radial-artery group and 1.4% in the saphe-
nous-vein group; odds ratio, 0.71; 95% CI, 0.23 
to 2.11; P = 0.53).
Subgroup Analyses
A nominally significant interaction between age 
and the treatment effect on major adverse car-
diac events was found (P = 0.04), and an age of 
75 years was identified as the cutoff for the loss 
of benefit from the radial artery. The interaction-
term analysis (Fig. 2) showed a greater benefit 
with regard to major adverse cardiac events in 
association with radial-artery grafts than with 
saphenous-vein grafts in patients younger than 
75 years of age (P = 0.008), in women (P = 0.01) 
and, nominally, in patients without renal insuf-
ficiency (P = 0.02). Diabetes (P = 0.35), a left ven-
tricular ejection fraction of less than 35% 
(P = 0.37), and previous myocardial infarction 
(P = 0.45) did not modify the treatment effect. 
The radial-artery-graft target vessel did not signifi-
cantly influence the treatment effect (P = 0.42).
The risk factors for occlusion of radial-artery 
grafts and saphenous-vein grafts are shown in 
Table S4 in the Supplementary Appendix. Age 
was found to be an independent predictor of 
radial-artery-graft occlusion but not saphenous-
vein-graft occlusion. Female sex was found to be 
associated with a lower risk of radial-artery-graft 
occlusion and higher risk of saphenous-vein-
graft occlusion. Long-term use of calcium chan-
nel antagonist therapy was found to be associated 
with a nominally significantly lower risk of radial-
artery-graft occlusion (details of the agents used 
to prevent arterial-graft spasm are provided in 
Table S5 in the Supplementary Appendix).
Discussion
In this patient-level combined analysis of ran-
domized, controlled trials comparing the radial 
artery and the saphenous vein as a second con-
duit for CABG, the use of radial-artery grafts 
was associated with a significantly lower risk of 
Figure 1. Cumulative Incidence of the Primary Compos-
ite Outcome of Death, Myocardial Infarction, or Repeat 
Revascularization and of Graft Failure in the Intention-
to-Treat Analysis.
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the composite outcome of death, myocardial in-
farction, or repeat revascularization and with a 
significantly lower risk of two individual compo-
nents of the outcome — myocardial infarction 
and repeat revascularization — at a mean follow-
up of 5 years. The use of radial-artery grafts was 
also associated with higher rates of angiographic 
patency at protocol-defined angiography, a find-
ing that offers a biologic mechanism to explain 
the observed advantage in clinical outcomes.
The clinical benefit associated with the use of 
radial-artery grafts seemed more evident in pa-
tients younger than 75 years of age, in women, 
and in patients without renal insufficiency. The 
target vessel of the radial-artery graft was not 
found to be a significant effect modifier. Because 
the attrition rate of saphenous-vein grafts but 
not of radial-artery grafts increases almost expo-
nentially with time,12 it is as yet unknown wheth-
er the clinical difference in outcome that is ap-
parent between the groups at 5 years could 
increase with a longer follow-up period.
The use of multiple arterial grafts is recom-
mended by current guidelines and the position 
papers of professional societies, predominantly 
on the basis of large observational studies that 
have reported a benefit with regard to outcomes 
after CABG.13-15 Despite these recommendations, 
arterial grafts have not been widely adopted; in 
the United States, less than 10% of patients who 
undergo elective CABG receive more than one 
arterial graft, and a radial-artery graft is used in 
less than 7%.1 One of the reasons for their infre-
quent use is that the superior clinical outcomes 
associated with multiple arterial grafts that have 
been reported in registries have not been repli-
cated in the randomized, controlled trials. There 
is concern that observational studies can be biased 
in favor of arterial conduits by unmatched con-
founders related to the unmeasurable (and un-
Figure 2. Subgroup Analyses and Interaction Terms for the Primary Composite Outcome of Death, Myocardial Infarction, or Repeat 
 Revascularization.
The P values given are the P values for the interaction-term analyses. Renal insufficiency was defined as a preoperative serum creatinine 
level of more than 1.5 mg per deciliter.3 LCX denotes left circumflex coronary artery, LVEF left ventricular ejection fraction, and RCA right 
coronary artery.
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matchable) judgment of the operating surgeons.16 
None of the randomized, controlled trials that 
compared radial-artery grafts with saphenous-
vein grafts have individually shown a difference 
in clinical outcome.6-11 The present patient-level 
combined analysis aimed to overcome the limi-
tations of individual trials by pooling the data 
from those trials.
Our analysis also revealed that superior pa-
tency of radial-artery grafts did not translate into 
a significant difference in survival at 5 years. 
The traditional concept of a direct relationship 
between coronary graft patency and survival is 
both intuitive and biologically plausible and is 
indirectly supported by studies that show better 
survival among patients who receive a conduit 
with higher long-term patency when the graft is 
to the left anterior descending coronary artery.17,18 
However, although there is clear evidence that 
failure of grafts to the left anterior descending 
artery adversely affects survival, failure of grafts 
to other target vessels is more likely to result in 
nonfatal cardiac events.19,20
The present analysis has several limitations. 
Even when a combined-analysis approach is used, 
the overall number of patients is relatively small 
for a procedure as common as CABG. In addi-
tion, the patients who were enrolled in the six 
trials were highly selected. These aspects clearly 
limit the external validity of our work. The dif-
ferent trials used various surgical techniques, 
harvesting protocols, and postoperative second-
ary prevention regimens. Different trials also 
used various methods to evaluate the adverse 
events related to radial-artery harvesting, and a 
pooled analysis of data for this outcome was not 
possible. However, in all the individual trials, 
radial-artery harvesting was associated with only 
minor clinical symptoms and no overt hand-
related complications.
There are also several limitations of the pa-
tency analysis in our study. In the main analysis, 
protocol-directed angiography was performed in 
only approximately three quarters of trial par-
ticipants, and the patients for whom follow-up 
angiographic data were available differed in clini-
cal characteristics and risk from patients for 
whom such data were not available. In addition, 
two trials accounted for more than two thirds of 
all the angiographic data. However, we found no 
heterogeneity across the included trials. The use 
of protocol-directed angiography renders the esti-
mation of graft occlusion by means of clinically 
directed angiography difficult. Finally, the esti-
mates of rates of repeat revascularization in angio-
graphic trials may be inflated relative to those in 
clinical outcome studies, since repeat revascular-
ization may be driven by angiographic findings 
rather than clinical findings.
In summary, in a pooled analysis of random-
ized, controlled trials comparing radial-artery 
grafts and saphenous-vein grafts as the second 
conduit for CABG, the use of radial-artery grafts 
resulted in a significantly lower rate of major 
adverse cardiac events and a better patency rate 
at a postoperative follow-up of 5 years.
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